MPM Capital has been around since 1997 and to date has raised nearly $4.0 billion in capital. The firm is particularly skilled in life sciences and can invest across private and public companies. Recently, it announced the closing of its seventh venture fund, BioVentures 2018, with total committed capital of $400 million.
“We’re grateful for our investors’ support of BV2018, which will allow us to continue to pursue our proven company-building strategy with the goal of improving healthcare outcomes while creating value for our investors,” said Ansbert Gadicke, M.D., co-founder and Managing Director of MPM. “The opportunity to drive innovation in drug development is more attainable than ever before. We believe this is particularly true in oncology where MPM has 29 oncology portfolio investments and approximately $1 billion of capital dedicated to developing novel cancer therapies.”
What makes MPM unique is how they have set up organizationally. Its broader team is comprised of fifteen Executive Partners working in close collaboration with the investment team to jointly harness scientific creativity, entrepreneurship, and financial and business insights. The Executive Partner team includes senior biopharma leaders with decades of experience in drug discovery, clinical development and commercialization.
MPM’s team is involved in all aspects of company building, from identifying and evaluating new opportunities to creating companies and assuming senior leadership roles across the portfolio. Recent examples of companies founded and led by MPM Executive Partners include Harpoon Therapeutics and TCR 2 Therapeutics, both of which recently completed IPOs, and Mitobridge and Potenza Therapeutics, both of which were recently acquired.
“Over two decades of investing, MPM has developed long-standing and strategic partnerships with academia, biotech and large pharma,” said Luke Evnin, Ph.D., co-founder and Managing Director of MPM. “Vital to our objective of delivering new treatments to improve the lives of patients, these relationships support our ongoing discovery of next-generation translational science and provide financing and acquisition opportunities across our portfolio.”
